Frontlight ResearchEarly access
CompletedNo phase
Coordinating Opioid Use Treatment Through Medical Management With Infection Treatment (Project COMMIT)
Key facts
- Who runs it
- Yale University
- Where
- Greenville, Hershey, and New Haven, United StatesSee the 3 sites
- Trial code
- Status
- Completed
- People taking part
- 171 people enrolled
- Started
- 18 Aug 2020
- Ended
- 25 Apr 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ID/LAB
- TAU
- Record updated
- 14 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Adults able to provide written informed consent in English or Spanish
- Current hospitalization with a suspected or known bacterial or viral (HIV/HCV/HBV) infection including but not limited to bacteremia, Candidal fungemia, osteomyelitis, endophthalmitis, septic thrombophlebitis, infected pseudoaneurysm, endocarditis, skin/soft tissue infection (SSTI), or septic arthritis
- Current moderate-to-severe OUD (DSM-5)
- Willing to accept assignment to either ID/LAB or TAU, and to participate in research follow-up visits
Who cannot take part
- Severe medical or psychiatric disability making participation unsafe (e.g. imminent suicide risk)
- Allergy, hypersensitivity or medical contraindication to buprenorphine
- Moderate-severe liver impairment in the judgment of the study investigator
- Pregnancy, planning conception, or breast-feeding for female participants
- Preexisting enrollment on methadone or buprenorphine (SL-B) maintenance AND intending to remain on methadone or buprenorphine maintenance upon discharge (patients already under effective treatment for OUD do not represent the target population of untreated OUD patients entering hospitals, nor would we want to disrupt established effective treatment)
- Inability or unwillingness of subject to give informed consent
Where in United States
- Prisma HealthGreenville, United States
- Penn State Health Milton S. Hershey Medical CenterHershey, United States
- Yale New Haven HospitalNew Haven, United States
About the trial
What the trial wants to find out
This study seeks to test a new model of care (ID/LAB) in which opioid use disorder (OUD) is managed by infectious disease (ID) specialists and hospitalists concurrent with management of the OUD-related infections, using long-acting injectable buprenorphine (LAB), followed by referral as soon as possible after hospital discharge to community resources for long term treatment of OUD.
The 2 groups in the trial
- TAUExisting treatment, for comparison
Treatment as Usual (TAU).
- ID/LABTreatment being tested
Infectious Disease management of OUD with Long-Acting injectable buprenorphine (ID/LAB).
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Record updated
- 14 July 2026